Clinical Trials Logo

Hepatitis C, Chronic clinical trials

View clinical trials related to Hepatitis C, Chronic.

Filter by:

NCT ID: NCT02640482 Completed - Clinical trials for Chronic Hepatitis C Virus (HCV) Infection

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

ENDURANCE-2
Start date: November 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.

NCT ID: NCT02640157 Completed - Chronic Hepatitis C Clinical Trials

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

ENDURANCE-3
Start date: December 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study was to compare the safety and efficacy of ABT-493/ABT-530 to the combination of sofosbuvir (SOF) and daclatasvir (DCV) in adults with genotype 3 (GT3) chronic hepatitis C virus (HCV) infection.

NCT ID: NCT02639585 Recruiting - Clinical trials for Hepatitis C, Chronic

Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C

ESDAC
Start date: December 2015
Phase: Phase 4
Study type: Interventional

We perform this study to identity efficacy and safety of Daclatasvir and Asunaprevir in real practice.

NCT ID: NCT02638233 Recruiting - Chronic Hepatitis C Clinical Trials

Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy

Start date: September 2015
Phase: Phase 4
Study type: Interventional

Patients with chronic hepatitis C that are under opiate substitution therapy are likely to have psychiatric comorbidities such as depression; hence an Interferon based therapy is contraindicated. Additionally many of these patients have a borderline compliance, which makes it impossible to treat them at specialized hepatological centers. An ideal opportunity to treat this patients is treatment with DAAs (Direct Acting Antiviral) which can be administered daily together with the opiate substitution therapy at a low threshold facility.

NCT ID: NCT02636608 Completed - Chronic Hepatitis C Clinical Trials

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary

VERITAS
Start date: November 27, 2015
Phase:
Study type: Observational

The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO), work productivity and safety data of the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), ± dasabuvir (DSV), ± ribavirin in chronic hepatitis C virus infected participants.

NCT ID: NCT02636595 Completed - Hepatitis C Virus Clinical Trials

The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)

ENDURANCE-4
Start date: November 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of response to treatment by evaluating the percentage of subjects achieving a 12-week sustained virologic response (SVR12) after 12 weeks of treatment with ABT-493/ABT-530 and to evaluate the safety of the regimen in participants with chronic hepatitis C virus (HCV) genotype (GT) 4, 5, or 6 infection.

NCT ID: NCT02629172 Completed - Clinical trials for Chronic Hepatitis C Virus

Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1

Start date: January 5, 2016
Phase:
Study type: Observational

The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily practice in Japan.

NCT ID: NCT02628717 Completed - Cirrhosis Clinical Trials

Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)

AURIC
Start date: July 2013
Phase: N/A
Study type: Observational [Patient Registry]

Since the availability of interferon free direct acting antivirals (DAA) the centers authorized to prescribed these drugs in Austria submitted their data to a central data base (AURIC) using treatment regimes without interferon and ribavirin in patients with advanced liver disease (F3/4)

NCT ID: NCT02624063 Completed - Clinical trials for Hepatitis C, Chronic

Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)

Start date: December 2015
Phase: Phase 4
Study type: Interventional

The purpose of the study is to study the combination of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 1.

NCT ID: NCT02618928 Completed - Chronic Hepatitis C Clinical Trials

The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France

OPALE
Start date: December 15, 2015
Phase:
Study type: Observational

This study seeks to determine the effectiveness of the interferon-free ABBVIE REGIMEN ± ribavirin (RBV) in participants with chronic hepatitis C (CHC) virus in clinical practices across France.